# Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

> **NCT02581137** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Erythroplakia
- Hyperplasia
- Oral Cavity Carcinoma
- Oral Leukoplakia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Metformin Hydrochloride

## Key facts

- **NCT ID:** NCT02581137
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06-10
- **Primary completion:** 2017-10-12
- **Final completion:** 2026-12-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581137, "Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02581137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*